Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy

Journal of Biological Chemistry

Volumn 287, Issue 44, 2012, Pages 36978-36989

  König, Matthias ^a   Holzhütter, Hermann Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DETAILED KINETICS; GLUCOSE METABOLISM; HORMONAL REGULATION; INSULIN THERAPY; INSULIN TREATMENT; KINETIC MODELING; TYPE 2 DIABETES MELLITUS;

GLUCOSE; KINETIC THEORY; METABOLISM; PHYSIOLOGY;

INSULIN;

ADRENALIN; GLUCAGON; GLYCOGEN; INSULIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; GLYCOGEN ANALYSIS; GLYCOGEN METABOLISM; GLYCOLYSIS; HIGH RISK POPULATION; HORMONAL REGULATION; HORMONE ACTION; HORMONE SUBSTITUTION; HYPOGLYCEMIA; INSULIN TREATMENT; KINETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION;

ALGORITHMS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; EPINEPHRINE; GLUCAGON; GLUCOSE; GLYCOGEN; HEPATOCYTES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KINETICS; LIVER; MODELS, BIOLOGICAL; PHOSPHORYLATION; POSTPRANDIAL PERIOD; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84868237294     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.382069     Document Type: Article

References (52)

1. Gerich, J. E. (1993) Control of glycaemia. Baillieres Clin. Endocrinol. Metab. 7, 551-586
2. Nuttall, F. Q., Ngo, A., and Gannon, M. C. (2008) Regulation of hepatic glucose production and the role of gluconeogenesis in humans. Is the rate of gluconeogenesis constant? Diabetes Metab. Res. Rev. 24, 438-458
3. Degenhardt, T. P., Thorpe, S. R., and Baynes, J. W. (1998) Chemical modification of proteins by methylglyoxal. Cell Mol. Biol. 44, 1139-1145
4. Baynes, J. W., and Thorpe, S. R. (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48, 1-9
5. Brownlee, M. (2005) The pathobiology of diabetic complications. A unifying mechanism. Diabetes 54, 1615-1625
6. Skyler, J. S. (1996) Diabetic complications. The importance of glucose control. Endocrinol. Metab. Clin. North Am. 25, 243-254
7. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986
8. Cryer, P. E. (1993) Glucose counterregulation. Prevention and correction of hypoglycemia in humans. Am. J. Physiol. 264, E149-E155
9. Basu, A., Dalla Man, C., Basu, R., Toffolo, G., Cobelli, C., and Rizza, R. A. (2009) Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 32, 866-872
10. Féry, F., Melot, C., and Balasse, E. O. (1993) Glucose fluxes and oxidation after an oral glucose load in patients with noninsulin-dependent diabetes mellitus of variable severity. Metabolism 42, 522-530
11. Israelian, Z., Szoke, E., Woerle, J., Bokhari, S., Schorr, M., Schwenke, D. C., Cryer, P. E., Gerich, J. E., and Meyer, C. (2006) Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 55, 593-598
12. Segel, S. A., Paramore, D. S., and Cryer, P. E. (2002) Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51, 724-733
13. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33, S62-S69
14. Cryer, P. E. (2007) Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 3, 4-5
15. Diabetes Control and Complications Trial Research Group (1991) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am. J. Med. 90, 450-459
16. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail-Beigi, F., Grimm, R. H., Jr., Probstfield, J. L., Simons-Morton, D. G., and Friedewald, W. T. (2008) Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559
17. ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C. E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B. E., Joshi, R., and Travert, F. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572
18. König, M., Bulik, S., and Holzhütter, H. G. (2012) Quantifying the contribution of the liver to glucose homeostasis. A detailed kinetic model of human hepatic glucose metabolism. PLoS Comput. Biol. 8, e1002577
19. Van Berkel, T. J., Kruijt, J. K., Van den Berg, G. B., and Koster, J. F. (1978) Difference in the effect of glucagon and starvation upon L-type pyruvate kinase from rat liver. Eur. J. Biochem. 92, 553-561
20. Beavo, J. A., Bechtel, P. J., and Krebs, E. G. (1974) Activation of protein kinase by physiological concentrations of cyclic AMP. Proc. Natl. Acad. Sci. U.S.A. 71, 3580-3583
21. Ishibashi, H., and Cottam, G. L. (1978) Glucagon-stimulated phosphorylation of pyruvate kinase in hepatocytes. J. Biol. Chem. 253, 8767-8771
22. Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., and Shulman, G. I. (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C-nuclear magnetic resonance study. J. Clin. Invest. 90, 1323-1327
23. Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Dalla Man, C., Cobelli, C., Cline, G. W., Shulman, G. I., Waldhäusl, W., and Roden, M. (2004) Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53, 3048-3056
24. Ferrannini, E., Simonson, D. C., Katz, L. D., Reichard, G., Jr., Bevilacqua, S., Barrett, E. J., Olsson, M., and DeFronzo, R. A. (1988) The disposal of an oral glucose load in patients with noninsulin-dependent diabetes. Metabolism 37, 79-85
25. Bogardus, C., Lillioja, S., Howard, B. V., Reaven, G., and Mott, D. (1984) Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J. Clin. Invest. 74, 1238-1246
26. Rizza, R. A. (2010) Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes. Implications for therapy. Diabetes 59, 2697-2707
27. Akram, K., Pedersen-Bjergaard, U., Borch-Johnsen, K., and Thorsteinsson, B. (2006) Frequency and risk factors of severe hypoglycemia in insulintreated type 2 diabetes. A literature survey. J. Diabet. Complications 20, 402-408
28. Hirsch, I. B. (2005) Insulin analogues. N. Engl. J. Med. 352, 174-183
29. Swinnen, S. G., Hoekstra, J. B., and DeVries, J. H. (2009) Insulin therapy for type 2 diabetes. Diabetes Care 32, S253-S259
30. Cryer, P. E., Davis, S. N., and Shamoon, H. (2003) Hypoglycemia in diabetes. Diabetes Care 26, 1902-1912
31. Ali, S., and Drucker, D. J. (2009) Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 296, E415-E421
32. Sloop, K. W., Michael, M. D., and Moyers, J. S. (2005) Glucagon as a target for the treatment of type 2 diabetes. Expert. Opin. Ther. Targets 9, 593-600
33. Yan, H., Gu, W., Yang, J., Bi, V., Shen, Y., Lee, E., Winters, K. A., Komorowski, R., Zhang, C., Patel, J. J., Caughey, D., Elliott, G. S., Lau, Y. Y., Wang, J., Li, Y. S., Boone, T., Lindberg, R. A., Hu, S., and Véniant, M. M. (2009) Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J. Pharmacol. Exp. Ther. 329, 102-111
34. Nauck, M. A., Kleine, N., Orskov, C., Holst, J. J., Willms, B., and Creutzfeldt, W. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36, 741-744
35. Butler, P. C., and Rizza, R. A. (1991) Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40, 73-81
36. Henkel, E., Menschikowski, M., Koehler, C., Leonhardt, W., and Hanefeld, M. (2005) Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54, 1168-1173
37. Knop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., and Krarup, T. (2007) Inappropriate suppression of glucagon during OGTT but not during isoglycaemic intravenous glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50, 797-805
38. Lerche, S., Soendergaard, L., Rungby, J., Moeller, N., Holst, J. J., Schmitz, O. E., and Brock, B. (2009) No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like peptide-1 administration in fasting healthy subjects. Clin. Endocrinol. 71, 500-506
39. Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., and Gerich, J. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326, 22-29
40. Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., Han, J., Taylor, K., Fineman, M., and Schmitz, O. (2004) Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53, 2397-2403
41. Levy, C. J., Kinsley, B. T., Bajaj, M., and Simonson, D. C. (1998) Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 21, 1330-1338
42. Mitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., and Gerich, J. (1991) Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am. J. Physiol. 260, E67-E74
43. Jones, T. W., Porter, P., Sherwin, R. S., Davis, E. A., O'Leary, P., Frazer, F., Byrne, G., Stick, S., and Tamborlane, W. V. (1998) Decreased epinephrine responses to hypoglycemia during sleep. N. Engl. J. Med. 338, 1657-1662
44. Müller, W. A., Faloona, G. R., Aguilar-Parada, E., and Unger, R. H. (1970) Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 283, 109-115
45. Spellman, C. W. (2010) Pathophysiology of type 2 diabetes: targeting islet cell dysfunction. J. Am. Osteopath. Assoc. 110, S2-S7
46. Consoli, A., Nurjhan, N., Capani, F., and Gerich, J. (1989) Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38, 550-557
47. Woerle, H. J., Szoke, E., Meyer, C., Dostou, J. M., Wittlin, S. D., Gosmanov, N. R., Welle, S. L., and Gerich, J. E. (2006) Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 290, E67-E77
48. Gastaldelli, A., Toschi, E., Pettiti, M., Frascerra, S., Quiñones-Galvan, A., Sironi, A. M., Natali, A., and Ferrannini, E. (2001) Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50, 1807-1812
49. Wajngot, A., Chandramouli, V., Schumann, W. C., Ekberg, K., Jones, P. K., Efendic, S., and Landau, B. R. (2001) Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50, 47-52
50. Boden, G., Chen, X., and Stein, T. P. (2001) Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 280, E23-E30
51. Basu, R., Basu, A., Johnson, C. M., Schwenk, W. F., and Rizza, R. A. (2004) Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 53, 2042-2050
52. Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., Defronzo, R. A., and Ferrannini, E. (2006) The effect of rosiglitazone on the liver. Decreased gluconeogenesis in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 806-812